Nohla Therapeutics Inc., a Seattle, WA-based developer of cellular therapies for haematological disorders and immunological diseases, closed a US$21M first round of funding.
In conjunction with the funding, the Chief Investment Officer and Founder of Scientia Capital, Mr. Lawrence Gozlan will join Nohla’s Board of Directors.
Led by Benjamin Bergo, CEO, and Michael Sistenich, Chief Business Officer, Nohla Therapeutics is a clinical stage company developing cellular therapies. Leveraging technology developed over the past two decades at the Fred Hutchinson Cancer Research Center, the company’s lead product is an ex vivo expanded hematopoietic stem and progenitor cell therapy derived from umbilical cord blood that is used clinically without any requirement for HLA matching.
It is available to all potential patients on demand at the time of treatment.